sotorasib
Amgen
['nsclc', 'sotorasib', 'sclc']
sotorasib more than doubled pfs at 12 months for patients with pretreated advanced #nsclc in a phase 3 trial, but other endpoints may raise questions. #esmo22 
OBR is an oncology-focused digital media company that provides news and information resources to oncology professionals.